Total submissions: 10
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Center for Genomic Medicine, |
RCV005229781 | SCV005872482 | likely pathogenic | not provided | 2025-03-04 | criteria provided, single submitter | clinical testing | |
| Center for Genomic Medicine, |
RCV004668716 | SCV005094448 | oncogenic | Neoplasm | 2025-03-04 | criteria provided, single submitter | clinical testing | |
| Myriad Genetics, |
RCV001823095 | SCV004931719 | likely pathogenic | Li-Fraumeni syndrome 1 | 2024-02-14 | criteria provided, single submitter | clinical testing | This variant is considered likely pathogenic. Functional studies indicate this variant impacts protein function [PMID: 15077194, 21561095, 29979965]. This variant is expected to disrupt protein structure [Myriad internal data]. |
| Liquid Biopsy and Cancer Interception Group, |
RCV003128570 | SCV003806291 | pathogenic | Squamous cell carcinoma | 2022-06-06 | criteria provided, single submitter | research | |
| Neuberg Centre For Genomic Medicine, |
RCV001823095 | SCV002073248 | pathogenic | Li-Fraumeni syndrome 1 | criteria provided, single submitter | clinical testing | The missense variant p.V157F in TP53 (NM_000546.6) has been reported previously in affected individuals (Zhang J et al,Goidescu IG et al). Functional studies reveal a damaging effect (Dearth LR et al; Calhoun S et al). The variant has been submitted to ClinVar as Pathogenic/Uncertain significance. The p.V157F variant is novel (not in any individuals) in gnomAD Exomes and is novel (not in any individuals) in 1000 Genomes. For these reasons, this variant has been classified as Pathogenic. | |
| Labcorp Genetics |
RCV000794324 | SCV000933724 | likely pathogenic | Li-Fraumeni syndrome | 2025-02-25 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 157 of the TP53 protein (p.Val157Phe). This variant is not present in population databases (gnomAD no frequency). This missense change has been observed in individuals with adrenocortical carcinoma, medulloblastoma and/or breast cancer (PMID: 15564800, 26580448, 29785153, 32899294). ClinVar contains an entry for this variant (Variation ID: 12353). Invitae Evidence Modeling incorporating data from in vitro experimental studies (PMID: 12826609, 29979965, 30224644) indicates that this missense variant is expected to disrupt TP53 function with a positive predictive value of 97.5%. Experimental studies have shown that this missense change affects TP53 function (PMID: 9472631, 10713666, 16861262). In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. |
| Gene |
RCV000566103 | SCV000821783 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2020-01-01 | criteria provided, single submitter | clinical testing | This sequence change replaces Valine with Phenylalanine at codon 157 of the TP53 protein (p.Val157Phe). The valine residue is highly conserved and there is a small physicochemical difference between valine and phenylalanine (Grantham Score 50)This sequence change has been reported in the literature in patients with breast, hepatocellular, and squamous cell carcinoma and adenocarcinoma (22187033 ,1672732 ). This variant is not present in population databases (rs121912654) but there is entries in the mutation database Clinvar (Variation ID: 12353). |
| Ambry Genetics | RCV000566103 | SCV000667202 | pathogenic | Hereditary cancer-predisposing syndrome | 2024-10-01 | criteria provided, single submitter | clinical testing | The p.V157F variant (also known as c.469G>T), located in coding exon 4 of the TP53 gene, results from a G to T substitution at nucleotide position 469. The valine at codon 157 is replaced by phenylalanine, an amino acid with highly similar properties. This variant has been reported in 1/1120 pediatric cancer patients who underwent whole genome sequencing and/or whole exome sequencing; this patient was diagnosed with adrenocortical carcinoma (Zhang J et al. N Engl J Med, 2015 Dec;373:2336-2346). This variant has also been reported as confirmed de novo in a 5 year-old patient who was diagnosed with medulloblastoma (Azzollini J et al. Cancers (Basel), 2020 Sep;12:). This variant is located in the DNA binding domain of the TP53 protein and is reported to have loss of transactivation capacity, a dominant negative effect, and is predicted to affect several p53 isoforms in yeast based assays (IARC TP53 databse; Dearth LR et al. Carcinogenesis, 2007 Feb;28:289-98; Baroni TE et al. Proc. Natl. Acad. Sci. U.S.A., 2004 Apr;101:4930-5; Gorgoulis VG et al. Br. J. Cancer, 1998;77:374-84; Ishii N et al. Oncogene, 1999 Oct;18:5870-8; Obata A et al. Int. J. Cancer, 2000 Mar;89:187-93; Concin N et al. Breast Cancer Res. Treat., 2003 May;79:37-46; Millon R et al. Oral Oncol., 2001 Dec;37:620-31; Fouquet C et al. Clin. Cancer Res., 2004 May;10:3479-89; Schlichtholz B et al. Carcinogenesis, 2004 Dec;25:2319-23; Scian MJ et al. Oncogene, 2004 May;23:4430-43; Mizuarai S et al. Cancer Res., 2006 Jun;66:6319-26; Kato S et al. Proc Natl Acad Sci USA. 2003 Jul 8;100(14):8424-9). Studies conducted in human cell lines are equivocal about this variant's ability to suppress cell growth (Kotler E et al. Mol.Cell. 2018 Jul;71:178-190.e8; Giacomelli AO et al. Nat. Genet. 2018 Oct;50:1381-1387). Based on internal structural analysis, this variant is anticipated to result in a significant decrease in structural stability of the DNA-binding domain (Kitayner et al. Nat. Struct. Mol. Biol., 2010 Apr;17(4):423-9; Calhoun S et al. Biochemistry, 2011 Jun;50:5345-53). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). This alteration has been observed numerous times as a somatic mutation in the cancerhotspots.org database (Chang MT et al. Cancer Discov. 2018 02;8:174-183). This amino acid position is not well conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. |
| German Consortium for Hereditary Breast and Ovarian Cancer, |
RCV000785500 | SCV000924072 | likely pathogenic | Ovarian neoplasm | 2018-12-01 | no assertion criteria provided | research | |
| OMIM | RCV000013147 | SCV000033394 | pathogenic | Hepatocellular carcinoma | 1991-04-04 | no assertion criteria provided | literature only |